How Much Upside is Left in Adma Biologics (ADMA)? Wall Street Analysts Think 52.85%

Core Viewpoint - ADMA Biologics (ADMA) shows potential for significant upside, with a mean price target of $26 indicating a 52.9$17.01 [1] Price Targets - The average price target consists of three estimates ranging from $25 to$28, with a standard deviation of $1.73, suggesting a consensus among analysts [2] - The lowest estimate indicates a 47% increase, while the highest suggests a 64.6% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price movement [7] Analyst Sentiment - Analysts have shown increasing optimism about ADMA's earnings prospects, as evidenced by upward revisions in EPS estimates [9] - The Zacks Consensus Estimate for the current year has increased by 1.5% due to one upward revision and no negative revisions in the last 30 days [10] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [11] Caution on Price Targets - Solely relying on price targets for investment decisions may not be wise, as they can often mislead investors [3][5][8] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [6]